Cancer treatment startup picks up additional $35M for Series A
January 22, 2021
Plexium has raised $35 million in a funding co-led by Lux Capital and Pivotal BioVentures, with participation from investors including The Column Group and DCVC Bio. The new capital brings the company's Series A total to $63 million. Based in San Diego, Plexium is a developer of protein degrading therapeutics designed to treat cancer and other diseases.